Efficacy of a novel oral carbapenem, tebipenem pivoxil (TBM-PI), against experimental otitis media caused by penicillin resistant Streptococcus pneumoniae in chinchilla

Vaccine. 2007 Mar 22;25(13):2478-84. doi: 10.1016/j.vaccine.2006.09.023. Epub 2006 Sep 20.

Abstract

An animal model of otitis media using chinchillas was developed to evaluate the efficacy of tebipenem pivoxil (TBM-PI) against experimental otitis media. Chinchillas inoculated via the transbullar approach with Streptococcus pneumoniae serogroup 6 were included in the efficacy study with TBM-PI, amoxicillin (AMX) or untreated as controls. TBM-PI resulted in survival rate of 83%, compared with 25% survival for AMX and 0% survival for controls (p<0.01). Quantitative cultures in the middle ear effusions at day 5 of the TBM-PI group yielded 3.5+/-2.4log(10)CFUs/ml. TBM-PI is a promising antibiotic for the treatment of acute otitis media.

MeSH terms

  • Administration, Oral
  • Amoxicillin / pharmacokinetics
  • Amoxicillin / pharmacology
  • Animals
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology*
  • Carbapenems / pharmacokinetics
  • Carbapenems / pharmacology*
  • Chinchilla
  • Male
  • Models, Animal
  • Otitis Media / drug therapy*
  • Otitis Media / metabolism
  • Otitis Media / microbiology
  • Penicillin Resistance
  • Pneumococcal Infections / drug therapy*
  • Pneumococcal Infections / metabolism
  • Streptococcus pneumoniae / isolation & purification*

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Amoxicillin
  • tebipenem